Degenerative Cervical Myelopathy Repository
DCM
Development of a Predictive Outcome Model for Patients With Degenerative Cervical Myelopathy Using Objective Functional and Biological Measures.
1 other identifier
observational
245
1 country
1
Brief Summary
To create a research repository of patients with known degenerative cervical myelopathy (DCM) and a control cohort of subjects who have non-myelopathic spinal disease. This repository will be used to assess functional and/or biological measures that may allow for improved prediction of symptomatic progression and response to treatment in patients with DCM. In addition, this repository will be used to develop a risk assessment scale to accurately predict functional outcomes following operative management of DCM.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 1, 2022
CompletedFirst Posted
Study publicly available on registry
July 6, 2022
CompletedStudy Start
First participant enrolled
July 13, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 1, 2028
February 13, 2026
February 1, 2026
4.9 years
July 1, 2022
February 10, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Data comparison between DCM and control groups
This study is to determine biomarkers associated with DCM and analyze objective clinical measures to determine more predictable and potentially effective treatments for patients diagnosed with cervical myelopathy.
2 years
Study Arms (2)
DCM group
Subjects diagnosed with degenerative cervical myelopathy.
Control group
Subjects diagnosed with cervical spinal disease without myelopathic symptoms.
Interventions
Standard of care surgical interventions, imaging impressions, laboratory results, and outcome measurements will be collected and analyzed.
Eligibility Criteria
The study population will be those diagnosed with degenerative cervical myelopathy, and those with cervical degenerative disease who do not experience myelopathic symptoms. Participating subjects will be required to sign the approved informed consent.
You may qualify if:
- Diagnosis of degenerative cervical myelopathy
- Diagnosis of cervical degenerative disease without myelopathy
You may not qualify if:
- None outside or diagnostic requirements and age limits.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Francis Farhadilead
Study Sites (1)
University of Kentucky
Lexington, Kentucky, 40536, United States
Biospecimen
Blood specimens will be collected and banked for future IRB approved research studies.
Study Officials
- PRINCIPAL INVESTIGATOR
Francis Farhadi, MD, PhD
University of Kentucky
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Target Duration
- 2 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
July 1, 2022
First Posted
July 6, 2022
Study Start
July 13, 2022
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
May 1, 2028
Last Updated
February 13, 2026
Record last verified: 2026-02